Bank of America’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Bank of America’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-31	Closed	-$9	–	8581
2024 Q2	$9	Buy	+31	New	+$74	﹤0.01%	8101
2024 Q1	–	Sell	-1	Closed	-$13	–	8303
2023 Q4	$13	Buy	+1	New	+$13	﹤0.01%	7742
2023 Q3	–	Sell	-4	Closed	-$83	–	8016
2023 Q2	$83	Hold	4	–	–	﹤0.01%	7436
2023 Q1	$35	Buy	4 +2	+100%	+$24	﹤0.01%	7539
2022 Q4	$20	Buy	+2	New	+$25	﹤0.01%	7996
2021 Q3	–	Sell	-1,083	Closed	-$268K	–	8480
2021 Q2	$268K	Hold	1,083	–	–	﹤0.01%	5877
2021 Q1	$261K	Buy	+1,083	New	+$266K	﹤0.01%	5847

Other funds holding EFTR

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bank of America's EFTR Position: Q3 2024 in Review

Bank of America sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 31 shares — an estimated $9 sold.

Bank of America first reported a position in EFTR in Q1 2021 and held it in 7 quarters. The position peaked at $268K in Q2 2021. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

Bank of America reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Bank of America sold 31 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $9.
Bank of America first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Bank of America's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $268K in Q2 2021.
3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.